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Steroid induction of responsive genes functions
through the synergistic activity of steroid receptor-
binding sequences with adjacent transcription fac-
tor-binding sites. To analyze the mechanism of syn-
ergy we tested different human glucocorticoid re-
ceptor mutants for synergistic function with another
transcription factor in comparison with intrinsic
trans-activation obtained with a single receptor bind-
ing site (glucocorticoid response element). Multiple
domains were found to be involved in synergistic
activity of the glucocorticoid receptor with the
CACCC box factor. Deletions within the N-terminal
receptor half affected simultaneously intrinsic trans-
activation and synergism. However, deletion of the
hormone-binding domain mainly impaired synergism
rather than intrinsic frans-activation, clearly showing
that this domain synergizes by a mechanism inde-
pendent of intrinsic activation. A chimeric protein
where the DNA-binding domain of the glucocorticoid
receptor was replaced by that of the yeast GAL4
protein also showed functional synergism. These
data suggest that some of the receptor domains
outside the DNA-binding domain synergize by their
intrinsic frans-activating property, but the hormone-
binding domain contributes to synergism by a dif-
ferent mechanism. (Molecular Endocrinology 5:
1498-1503, 1991)
INTRODUCTION
Regulatory elements distant from the transcriptional
start site are often composed of multiple binding sites
for different transcription factors cooperating for full
activity (see Ref. 8 for review). In the case of steroid
hormone-responsive genes, the central transcription
factor involved is the hormone receptor, which binds to
a specific DNA sequence. This hormone-responsive
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element consists of a short palindromic sequence (see
Ref. 3 for review). Synergistic activity has been dem-
onstrated both between two adjacent palindromic re-
ceptor-binding sites (1,7,15,25) and between a steroid
receptor-binding site and any other transcription factor
recognition sequence tested (25-27). Thus, the final
transcriptional activity of a hormone-dependent gene
results from two effects: the intrinsic frans-activation
mediated by the glucocorticoid receptor alone and the
synergism resulting from adjacent binding of a second
receptor or another transcription factor. For duplicated
glucocorticoid or progesterone receptor-binding sites,
increased DNA-binding affinities have been demon-
strated (22, 24, 30), a mechanism that is also found in
some cases for the estrogen receptor (15, 19, 22).
Binding cooperativity apparently is not involved in the
synergism of the glucocorticoid receptor with other
transcription factors (20), although one exception has
been found (4).
The requirement for a stereospecific alignment of the
synergizing factors suggests direct or indirect interac-
tion between the proteins (22, 24-26). According to
recently proposed models, functional synergism (not
based on DNA-binding cooperativity) may involve the
interaction of frans-activating domains of transcription
factors with a common target, intermediary, or adaptor
protein which transmits the regulatory signal to the
transcription initiation complex (see Ref. 16 for review).
Trans-activating domains of synergizing factors may
touch a common adapter more efficiently than a single
transcription factor (23) or synergizing transcription fac-
tors may activate different stages in the initiation of
transcription (29). Such a mechanism predicts that syn-
ergism is mediated by the regular intrinsic frans-acti-
vation mechanism of the factors involved. Alternatively,
synergism may use a distinct mechanism mediated by
direct or indirect interaction of the receptor with the
neighboring transcription factor independent of its in-
trinsic frans-activation domains.
To find out whether synergism and intrinsic frans-
activation act on a common target, we determined both
activities for several receptor mutants. Both functions
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should be altered concomitantly if they are closely
linked. We now show that domains mediating trans-
activation and synergism are overlapping, but not al-
ways identical.
RESULTS
Receptor Domains Mediating Synergism with the
CACCC Box
We wanted to determine the contributions of different
parts of the human glucocorticoid receptor to synergism
with different transcription factors. Therefore, we co-
transfected an expression plasmid coding for the hu-
man glucocorticoid receptor in its wild-type or mutant
form along with a reporter plasmid into T47D cells
[which lack functional glucocorticoid receptor (6)]. The
transcriptional activity of a reporter gene regulated by
a receptor-binding sequence depends on several prop-
erties of the receptor: DNA binding, hormone binding,
nuclear translocation, dimerization, protein stability,
frans-activation, and synergistic interaction with tran-
scription factors bound on adjacent sequences. To
analyze only the synergistic function of receptor mu-
tants, we compared the activity of a reference (control)
reporter gene (pG29C*tkCAT) to that of a test reporter
gene (pG29CtkCAT). The test reporter gene
(pG29CtkCAT) contained a single imperfect palindromic
receptor-binding site, as found in the long terminal
repeat of the mouse mammary tumor virus, fused to a
functional CACCC sequence originating from the rat
tryptophan oxygenase gene (26). A distance of 29
basepairs (bp) separating the two binding sites had
been shown to be optimal for synergism (26). This
hormone-responsive unit was linked at position -105
to the thymidine kinase (tk) promoter, which, in turn,
controlled the expression of the chloramphenicol acetyl
transferase (CAT) gene (Fig. 1) (26). The reference
(control) reporter gene (pG29C*tkCAT) contains a mu-
tagenized CACCC (C*) replacing the wild-type se-
quence. The C* sequence does not bind nuclear factors,
nor does it functionally synergize (26). In addition, the
glucocorticoid response element (GRE; -186 bp up-
stream of the transcriptional start site) does not syner-
gize with transcription factors bound to the tk promoter
(26). Thus, transcriptional activity of this gene is due to
the action of one isolated GRE and represents the
intrinsic frans-activation activity of the tested receptor.
CAT activities of these reporter constructs always re-
flected the amount of correctly initiated RNA (not
shown).
DNA transfections were performed using constant
amounts of reporter genes while increasing the concen-
tration of the respective receptor expression plasmid,
leading to increasing CAT activities. In this way the
slope within the linear range of the curve (Fig. 3)
achieved with the test reporter gene could be compared
to the slope seen with the control reporter gene. Syn-
ergism was measured as the ratio between the two
CAT SV40 polyA
pG 29 C* tkCAT
pG 29 C tkCAT
pUAS 29 C* tkCAT
pUAS 29 C tkCAT
Fig. 1. Schematic Representation of Reporter Plasmids
The reporter plasmids with the tk promoter, the CAT-coding
region, and various receptor (GRE)- and nonreceptor-binding
site combinations are shown. The nonreceptor-binding sites
(24) are a CACCC box and an up-stream activator sequence
(UAS) element. The mutagenized nonbinding CACCC box is
indicated (*)•
slopes. This strategy enables analysis even of those
receptors that lead to only weak transcriptional stimu-
lation and corrects for varying amounts of different
mutated receptor species present within the cells.
Within a wide range of expression plasmid concentra-
tions, reporter gene activity increased linearly. Intrinsic
frans-activation of wild-type and mutant receptors was
determined with the control reporter gene
(pG29C*tkCAT) at a constant amount of expression
plasmid and agreed with the published values (13). The
characterized domains of the receptor are indicated in
Fig. 2: frans-activating domains TI and T2 (13), the DNA-
binding domain (DNA), and the hormone-binding domain
(HBD)(12).
Cotransfections of the wild-type receptor expression
plasmid with reporter plasmids pG29C*tkCAT and
pG29CtkCAT confirmed the synergistic effect of the
CACCC sequence on steroid induction (Fig. 3 and Table
1). The receptor deletion mutants can be categorized
into four groups according to their synergizing proper-
ties, a prototype for each of these categories is shown
in Fig. 3. Only the wild-type receptor belongs to the first
category, showing high activities in both synergism and
intrinsic frans-activation. The second category (mutant
1-550) shows a high intrinsic frans-activation, as high
as the wild-type receptor, but only a moderate syner-
gistic activity. This mutant is a clear example that
intrinsic frans-activation and synergism do not neces-
sarily colocalize on the receptor. Another example of
this kind is demonstrated by the third category, which
shows the same moderate level of synergism as the
second category, but exerts about a 10-fold reduced
intrinsic frans-activation. A prototype of this category is
mutant 1-515 (Fig. 3D), which shows effects similar to
those of mutants A77-262, A262-418, 418-777, and
1-488 (Table 1). The fourth category is characterized
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Fig. 2. Schematic Representation of Expression Plasmids
The different domains of the wild-type human glucocorticoid
receptor are shown: the hormone-binding domain (HBD), trans-
activation domains T1 and T2, and the DNA-binding domain
(DNA). The regions deleted in each mutant are indicated with
a line, and the deletion end points are given. GR-GAL-GR is
shown, and the end points of the human glucocorticoid recep-
tor parts are indicated as well as the GAL4 DNA-binding
domain (GAL4).
measurable compared with the nonbinding mutant 1 -
468; Table 1) and no detectable synergism (Fig. 3B and
Table 1; mutants 418-515 and 418-488).
In conclusion, all of the tested deletion mutants of
the glucocorticoid receptor affect the synergism with a
neighboring CACCC box factor. Intrinsic frans-activa-
tion is clearly impaired as well, but both functions do
not change coordinately in some mutants. This is an
indication that intrinsic frans-activation and synergism
do not necessarily follow identical mechanistic path-
ways.
Domains outside the DNA-Binding Domain
Contribute to Synergism
As all of the mutants tested above showing synergism
still contained the DNA-binding domain, the question
arises of whether this domain might be responsible for
the observed synergism. Such a function may be un-
detectable in mutant 418-488, containing only the
DNA-binding domain, since its intrinsic frans-activation
is very low. To address this question, we decided to
construct a chimeric protein where the DNA-binding
domain of the receptor was replaced by the DNA-
binding domain of the GAL4 protein (GR-GAL-GR).
Similar fusion proteins have been used before to test
for function of isolated domains of DNA-binding proteins
(13, 18, 31). Amino acids 1-147 of the GAL4 protein
contain all of the properties necessary for dimerization
(5) and specific binding to the palindromic UAS se-
quence, but do not lead to frans-activation (14) or
cooperative binding to a duplicated binding site (10).
When only this domain is expressed in T47D cells, no
effect whatsoever was detectable on any UAS-contain-
ing reporter plasmid (data not shown). When the fusion
protein GR-GAL-GR was expressed, a strong intrinsic
frans-activation was seen using the reporter gene UAS-
C* containing a single GAL4-binding site. When the
reporter UAS-C was used, harboring a UAS element
adjacent to a CACCC box, a strong synergism was
seen (Fig. 4). Comparison of the slopes of the curves
obtained with the control reporter (UAS-C*) and the test
reporter plasmid (UAS-C) showed a 5-fold synergism of
GR-GAL-GR with the neighboring CACCC factor. This
observation clearly shows that domains outside the
receptor DNA-binding domain contribute to funtional
synergism.
DISCUSSION
Models for synergistic frans-activation have been sug-
gested previously. They involve interaction of the trans-
activating domains with a protein called target, adaptor,
or intermediary factor (see Ref. 16 for review), trans-
mitting the regulatory signal to the transcriptional start
site. In one model two transcription factors would sim-
ply provide a larger surface for such an interaction (23).
Another model suggested that different frans-activating
domains would activate different stages in the initiation
of transcription and would, therefore, be able to syner-
gize (29). Both models are similar in predicting that
synergism is conferred by the frans-activating pathway.
An alternative model involves an additional protein con-
tacting specific domains of the two synergizing factors.
To test whether synergism is mediated by the intrinsic
frans-activating pathway, we tested several receptor
deletions for their synergistic capacity with the CACCC
box. Most of the receptor deletions affect both the
synergism and the frans-activation even when regions
outside the T1 and T2 domains are deleted. This con-
firms the notion that the glucocorticoid receptor may
comprise at least four frans-activating functions (28).
The synergism and frans-activation observed with re-
ceptor mutants was not due to the receptor DNA-
binding domain alone, present in all of the mutants, as
the replacement of this domain with the DNA-binding





























Fig. 3. Synergism of Glucocorticoid Receptor Mutants with the CACCC Box Binding Protein
The graphs show CAT activities achieved after transfection of increasing amounts of wild-type or mutant receptor expression
vector (picomoles of receptor DNA per transfection) together with constant amounts of pG29C*tkCAT (O) or pG29CtkCAT (•)
reporter plasmids. CAT activity is expressed as picomoles of acetylated chloramphenicol per mg protein/min. The expression
plasmids used are the wild-type receptor (A; hGRwt) or mutant 418-488 (B), mutant 1-550 (C), and mutant 1-515 (D). The graph
was calculated by linear regression, and the SD (shaded area) was determined according to standard procedures (21).
Table 1. Synergism of Glucocorticoid Receptor Mutants with


































 Fold synergism is defined as the ratio between the slopes
achieved with pG29CtkCAT and pG29C*tkCAT (see Fig. 3).
NA, Not applicable.
b
 Intrinsic frans-activation is determined with 0.1 pmol receptor
expression plasmid and 1.5 pmol pG29C*tkCAT.
domain of the yeast protein GAL4 results in a protein
that is able to both frans-activate and synergize. We
cannot rule out the possibility that the DNA-binding
domain of the receptor might contribute to synergism,
since the construct GR-GAL-GR is less efficient in
synergizing than the wild-type receptor and since the
DNA-binding domain of the receptor shows some
(weak) frans-activation if tested alone. On the other
hand, this difference in synergism may be due to non-
optimal conformation of the receptor in the GAL fusion
protein. In addition to the colocalization of frans-acti-
vating and synergizing receptor properties, one impor-
tant exception was found, deletion of the hormone-
binding domain reduced the synergism with the CACCC
box factor by about 3-fold, whereas the intrinsic trans-
activation of this receptor mutant tested in isolation is
only marginally reduced (~0.8-fold). Such a finding ar-
gues for the presence of an additional factor, which
may contact the hormone-binding domain and the
CACCC box protein simultaneously.
In summary, the puzzling finding that every combi-
nation of the glucocorticoid receptor with other tran-











Fig. 4. Synergism of a GAL4-Glucocorticoid Receptor Fusion
Protein with the CACCC Box Binding Protein
The graph shows CAT activities achieved after transfection
of increasing amounts of pRS GR-GAL-GR (picomoles of
expression vector DNA per transfection) together with con-
stant amounts of pUAS29C*tkCAT (O) or pUAS29CtkCAT (•)
reporter plasmids. For calculations, see Fig. 3.
duction (25-27) may be solved by the fact that particular
combinations may synergize via specific functions of
the multiple receptor domains. These functions include
cooperative binding in the case of receptor/receptor
synergism, the synergism mediated by several inde-
pendent frans-activating receptor functions, and a sy-
nergizing property of the hormone-binding domain not
using a strong frans-activating function.
MATERIALS AND METHODS
Plasmids
The constructs containing the indicator gene tk-CAT (CAT
gene fused to the tk promoter) and carrying binding sites for
the glucocorticoid receptor and the CACCC box have been
described previously (24). The pUAS 29 C*tkCAT and pUAS
29 CtkCAT were generated in an analogous fashion by replac-
ing the GREs by the binding site CGGAGGACTGTCCTCCG
(UAS) for the yeast GAL4 protein (10), with the corresponding
H/ndlll/Smal restriction sites at the 5' and 3' ends.
The expression vectors for wild-type human glucocorticoid
receptor (pRShGR) and for the receptor mutants A77-262,
I488,1 -515 (1515*), 1 -550 (I550*), and 1 -77/262-515 (GR15)
were kindly provided by R. M. Evans (9,13). Mutant 418-777
was generated by replacing a Hini\/Hind\\\ fragment (amino
acids 1-426) from pRShGR with a synthetic oligonucleotide
duplex (5' -ACTCC AG-C AGCC AG ATCTG ACCTCCCCCAAA-
CTCTGCCTGGTGTGCTCTGATGA-3'), thereby restoring the
otherwise deleted part of the DNA-binding domain (amino
acids 418-426). Mutant 1-488 was constructed by linearizing
I488 with BamHl, filling in with Klenow enzyme, followed by
religation, thereby inducing a frame shift in the natural se-
quence leading to 26 unrelated codons until a stop codon is
reached. Mutant 1-468 was constructed by linearizing
pRShGR with C/al, filling in with Klenow enzyme, followed by
religation. Mutants 418-515, 418-488, and 418-777/1488
were obtained by replacing the Kpn\/Hind\\\ fragment in 1 -515,
1-488, and I488, respectively with the Kpn\/Hind\\\ fragment
from 418-777. Mutant A262-418 was constructed by insert-
ing the Bgll\/Bgl\\ (amino acids 77-262) fragment from
pRShGR into the BglW site of 1-78/418-777.
The GAL4 DNA-binding domain expression vector pRS
GAL1-147 was constructed by joining an oligonucleotide du-
plex 5'GATCTGAAGCTACTGTCTCTATCGAACAAGCATG3'
to the Sph\ site of the Sph\/BamH\ fragment of pMA424 (17),
thereby restoring the first 10 amino acids of GAL1-147, fol-
lowed by insertion into the Bgl\\/BamH\ sites of mutant 418-
777/I488. The resulting plasmid contains linker sequences,
coding for 26 unrelated amino acids after amino acid 147.
The pRS GR-GAL-GR was generated by fusing the Kpn\/
Hind\\\ fragment (filled in with Klenow), containing the first 426
amino acids of human glucocorticoid receptor, into the Kpn\/
BglW sites (filled in with Klenow) of pRS GAL1 -147. In addition,
the EcoRI and BamH\ linker sites of pRS GAL1-147 were cut,
filled in with Klenow enzyme, and religated, leading to a frame
shift and thereby restoring the whole C-terminal part (amino
acids 488-777) of human glucocorticoid receptor.
Cell Culture and Transfection
T47D cells were transfected as previously described (2). All
test plasmids (1.5 pmol) were cotransfected with different
amounts of receptor expression vector, as indicated. Cells
were seeded in charcoal-depleted medium, and 5 x 10~7 M
dexamethasone was added. Endogeneous receptors did not
influence the results, since T47D cells do not have functional
glucocorticoid receptors (6), and the use of antihormone to-
gether with receptor mutants lacking hormone-binding domain
did not change the synergism. Cells were harvested and tested
for CAT activity 40 h after transfection (11). All transfections
were performed in triplicate. The complete series of transfec-
tions was performed at least twice. Cell extracts were heat
treated (10 min; 60 C) before carrying out the CAT assay.
CAT assay conditions were chosen to yield converson rates
between 0.5-60% of chloramphenicol and ranged from incu-
bation of 5 ^g cell protein for 30 min to 150 ng for 16 h.
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